Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2008-12-18
2010-11-09
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S133100, C424S134100, C424S136100, C424S141100, C424S143100, C424S153100, C424S154100, C424S173100, C530S387100, C530S387300, C530S388200, C530S388220, C530S388700, C530S388750, C536S023100, C536S023500, C536S023530, C435S252300, C435S320100, C435S326000, C435S343000, C435S343100
Reexamination Certificate
active
07829092
ABSTRACT:
The present invention disclosed recombinant anti-VLA-4 antibody molecules, including humanized recombinant anti-VLA-4 antibody molecules. These antibodies are useful in the treatment of specific and non-specific inflammation, including asthma and inflammatory bowel disease. In addition, the humanized recombinant anti-VLA-4 antibodies disclosed can be useful in methods of diagnosing and localizing sites of inflammation.
REFERENCES:
patent: 4816397 (1989-03-01), Boss et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4816587 (1989-03-01), Cabilly et al.
patent: 5217870 (1993-06-01), Hession et al.
patent: 5272263 (1993-12-01), Hession et al.
patent: 5367056 (1994-11-01), Hession et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5695755 (1997-12-01), Papayannopoulo
patent: 5824304 (1998-10-01), Papayannopoulo
patent: 5859205 (1999-01-01), Adair et al.
patent: 5871734 (1999-02-01), Lobb et al.
patent: 5888507 (1999-03-01), Burkly
patent: 5932214 (1999-08-01), Lobb et al.
patent: 6252043 (2001-06-01), Hession et al.
patent: 6307025 (2001-10-01), Hession et al.
patent: 6482409 (2002-11-01), Lobb et al.
patent: 6602503 (2003-08-01), Lobb et al.
patent: 7157086 (2007-01-01), Lobb et al.
patent: 7482003 (2009-01-01), Lobb et al.
patent: 0120694 (1984-10-01), None
patent: 0125023 (1984-11-01), None
patent: 0239400 (1987-09-01), None
patent: 0330506 (1989-08-01), None
patent: 0519596 (1992-12-01), None
patent: 86/01533 (1986-03-01), None
patent: 86/05807 (1986-09-01), None
patent: 87/04462 (1987-07-01), None
patent: 89/01036 (1989-02-01), None
patent: 89/07454 (1989-08-01), None
patent: 89/10404 (1989-11-01), None
patent: 90/07861 (1990-07-01), None
patent: 9013300 (1990-11-01), None
patent: 91/09967 (1991-07-01), None
patent: 92/04381 (1992-03-01), None
patent: 9519790 (1995-07-01), None
Harlan, “Leukocyte-Endothelial Interactions” Blood (1985) 65:513-526.
Marcantonio, et al., “Antibodies to the Conserved Cytoplasmic Domain of the Integrin β1 Subunit React with Proteins in Vertebrates, Invertebrates and Fungi” J. Cell. Biol. (1988) 106:1765-1772.
Pober, et al., “Overlapping Patterns of Activation of Human Endothelial Cells by Interleukin 1, Tumor of Necrosis Factor, and Immune Interferon” J. Immunol. (1986) 137:1893-1896.
Albelda et al., “Adhesion molecules and inflammatory injury”, FASEB J. (1994) 8:504-512.
Bebbington et al., “High-Level Expression of a Recombinant Antibody from Myeloma Cells Using a Glutamine Synthetase Gene as an Amplifiable Selectable Marker”, Bio/Technology (1992) 10: 169-175.
Bednarczyk et al., “A Monoclonal Antibody to VLAα Chain (CDw49d) Induces Hornotypic Lymphcyte Aggregation”, J. Immunol. (1990) 144:777-784.
Begent et al., “Phase I/II Study of Chimeric B72.3 Antibody in Radioimmunology of Colorectal Carcinoma” Br. J. Cancer (1990) 62:487.
Bevilacqua et al., “Endothelial Leukocyte Adhesion Moldecule 1: An Inducible Receptor for Neutrophils Related to Complement Regulatory Proteins and Lectins”, Science (1989) 243:1160-1165.
Bevilacqua et al., “Identifcation of an Inducible Endothelial-Leukocyte Adhesion Molecule” Proc. Natl. Acad. Sci USA (1987) 84:9238-9242.
Bochner et al., “Adhesion of Human Basophiols, Eosinophils, and Neutrophiles to Interleukin 1-activated Human Vascular Endothelial Cells: Contributions of Endothelial Cell Adhesion Molecules” J. Exp. Med (1991) 173:1553-1556.
Borrebaeck et al., “The Use of in Vitro Immunization, Cloning of Variable Regions, and SCID Mice for the Production of Human Monoclonal Antibodies”, Therapeutic Monoclonal Antibodies (1990) 1: 1-15.
Boyd et al., “Intercellular Adhesion Molecule 1 (ICAM-1) has a Central Role in Cell-Cell Contact-Mediated Immune Mechanisms” Proce. Natl. Acad. Sci USA (1988) 85:3095-3099.
Bruggemann et al. “The Immunogenicity of Chimeric Antibodies” J. Exp Med. (1989) 170:2153-2157.
Bulinkski, “Peptide Antibodies: New Tools for Cell Biology” International Review of Cytology (1986) 103:281-302.
Burkly et al., Eur J. Immunol. (1991) 21:2871-2875.
Carlos et al., “Vascular Cell Adhesion Molecule-1 Mediates Lymphocyte Adherence to Cytokine-Activated Cultured Human Endothelial Cells” Blood (1990) 76:965-970.
Clayberger et al., “Identification and Characterization of Two Novel Lymphocyte Function-Associated Antigens, L24 and L25” J. Immunol. (1987) 138:1510-1514.
Co et al., “Humanized Antibodies for Antiviral Therapy” Proc. Natl. Acad. Sci USA (1991) 88:2869-2873.
Collins et al., “Recombinant Human Tumor Necrosis Factor Increases mRNA Levels and Surface Expression of HLA-A, B Antigens in Vascular Endothelial Cells and Dermal Fibroblasts in Vitro” Proc. Natl. Acad. Sci USA 83:446-450, (1986).
Cybulsky et al., “Endothelial Expression of Mononuclear Leukocyte Adhesion Molecule During Atherogenesis” Science (1991) 251:788-791.
Dobrina et al., “Mechanisms of Eosinophil Adherence to Cultured Vascular Endothelial Cells” J. Clin. Invest. (1991) 88:20-26.
Dustin et al., “Lymphocyte Function-Associated Antigen-1 (LFA01) Interaction with Intercellular Adhesion Molecule-1 (ICAM-1) is One of At Least Three Mechanisms for Lymphocyte Adhesion to Cultured Endothelial Cells” J. Cell Biol. (1988) 107:321-331.
Dustin et al., “Induction by IL1 and Interferon-γ: Tissue Distribution, Biochemistry, and Function of a Natural Adherence Molecule (CAM-1)” J. Immunol. (1986) 137:245-254.
Edgington “How Sweet It Is: Selectin-Mediating Drugs” Bio/Technology (1992) 10:383:384.
Elices et al., “VCAM-1 on Activated Endothelium Interacts with the Leukocyte Integrin VLA4 at a Site Distinct from the VLA4/Fibronectin Binding Site” Cell (1990) 60:577-584.
Favoloro et al., “Transcriptional Maps of Polyoma Virus Specific RNA: Analysis by Two-Dimensional Nuclease S1 Gel Mapping” Methods in Enzymology (1980) 65:718-749.
Flanagan et al., “Arrangelemt of Human Immunoglobulin Heavy Chain COnstruct Region Genes Implies Evolutional Amplification of a Segment Containing γ, ε and α Genes” Nature (1982) 300:709-713.
Freedman et al., “Adhesion of Human B Cells to Germinal Centers in Vitro Involves VLA-4 and INCAM-110” Science (1990) 249:1030-1033.
Hale et al., “Remission Induction in Non-Hodgkin Lymphoma with Reshpaed Human Monoclonal Antibody CAMPATH-1H” Lancet (Dec. 17, 1988) 1394-1398.
Harian, “Leukocyte-Endothelial Interactions” Blood (1985) 65:513-526.
Harris et al., “Therapeutic antibodies—the coming of age” TIBTECH (1993) 11: 42-44.
Hemler, “VLA Proteins in the Integrin Family: Structures, Functions and Their Role on Leukocytes” Anny. Rev. Immunol. (1990) 8:365-400.
Hemler et al., “Characterization of the Cell Surface Heterodimer VLA4 and Related Peptides” J. Biol. Chem. (1991) 262:11476-11485.
Hession et al., “Cloning of an Alternative Form of Vascular Cell Adhesion Molecule-1 (VCAM1” J. Biol. Chem. (1980) 266:6682-6685.
Hieter et al., “Cloned Human and Mouse Kappa Immunoglobulin Constant and J Region Genes Conserve Homology in Functional Segments” Cell (1991) 22:197-207.
Ho et al., “Site-directed Mutagenesis by Overlap Extension Using the Polymerase Chain Reaction” Gene (1989) 77:51-59.
Holzmann et al., “Identification of a Murine Peyer's Patch-Specific Lymphocyte Homing Receptor as an Integrin Molecule with an α Chain Homologous to Human VLA-4α” Cell (1989) 56:37-46.
Huse et al., “Generation of a Large Combinatorial Library of Immunoglobulin Repertoire in Phage Lambda” Science (1989) 246:1275-1281.
Hynes, “Integrins: A Family of Cell Surface Receptors” Cell (1987) 48:549-554.
Issekutz, “Inhibition of in Vivo Lymphocyte Migration to Inflammation and H
Carr Frank J.
Lobb Roy R.
Tempest Philip R.
Biogen Idec MA Inc.
Gambel Phillip
Steptoe & Johnson LLP
LandOfFree
Recombinant anti-VLA4 antibody molecules does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant anti-VLA4 antibody molecules, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant anti-VLA4 antibody molecules will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4190742